Fortis opened higher at $58.74, compared with its previous close of $58.09. In the last trading session, the stock traded between $58.30 and $58.95. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Fortis is now worth
$ 132.24
giving a profit of
$ 32.24 (32.24%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
+$0.77 (+1.33%)
Day High
$58.95
Day Low
$58.30
Day Open
$58.74
Prev Close
$58.09
Volume
3,01,055
1W Return
1.74%
1M Return
10.96%
3M Return
2.18%
6M Return
4.66%
1Y Return
17.28%
Market Cap ($ Mn)
30,072
PE Ratio
22.22
PB Ratio
1.68
PEG Ratio
4.28
ROE
8.80%
ROCE
5.58%
EPS (TTM)
$0.78
1 Week
1.74%
1 Month
10.96%
3 Months
2.18%
6 Months
4.66%
9 Months
9.77%
CIBC raises Fortis price target to C$81, maintains Neutral rating
CIBC analyst Mark Jarvi raised Fortis' price target to C$81. The previous price target was set at C$78. Analyst maintains a Neutral rating on the stock. Price target increase represents a 3.8% uplift.
YesterdayFortis Inc. to release Q3FY27 results and new capital outlook
Fortis Inc. releases Q3 2026 results on November 3, 2026. New five-year capital outlook for 2027-2031 to be announced. Total assets stood at $79 billion as of June 30, 2026. Teleconference available via webcast and toll-free dial-in.
24 days agoFortis Inc. prices $1 billion in fixed-to-fixed junior subordinated notes
Fortis Inc. priced a $1 billion offering of junior subordinated notes due March 30, 2057. The deal includes $500 million at 6.625% and $500 million at 6.875% coupon rates. Morgan Stanley, MUFG, Wells Fargo, and BofA Securities co-led the underwriting syndicate. Net proceeds will fund repayment of maturing debt and general corporate purposes. Closing is expected on September 21, 2026, subject to customary conditions.
1mo agoHigh Court appoints forensic auditor to probe Fortis-Religare deal
A High Court appointed a forensic auditor to investigate the Fortis-Religare deal. The audit was initiated following a request by Sankyo in the case. The development places the Fortis-Religare transaction under formal judicial and forensic scrutiny.
2mo agoFortis Q1 Results: Sales Beat by 3%, EBITDA Misses by 130bps
Nomura maintained its Neutral rating on Fortis Healthcare with a target price of ₹990 following Q1FY27 results. Sales beat estimates by 3%, but EBITDA and EBITDA margin missed by 3% and 130bps respectively, partly due to a ₹307mn ESOP charge. Excluding a ₹95mn exceptional gain from impairment reversal, PAT was in line with estimates, reflecting steady underlying business performance.
2mo agoFortis Q2 Results: Sales beat estimate, EPS meets consensus
Fortis Healthcare reported Q2 EPS of $0.56, meeting consensus, while sales of $2.117 billion beat the $2.110 billion estimate. Revenue rose 4.08% YoY to $2.117 billion from $2.034 billion, while EPS grew 1.82% YoY from $0.55.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $82.14 | +1.38% | $1,72,272.71M | 18.39 | |
| $92.99 | +1.61% | $1,06,972.26M | 21.27 | |
| $125.90 | +1.89% | $98,164.48M | 18.11 | |
| $84.20 | +2.41% | $84,653.15M | 18.08 | |
| $129.34 | +0.89% | $70,428.99M | 21.20 | |
| $65.12 | +1.31% | $57,274.73M | 22.68 | |
| $85.89 | +1.44% | $56,163.47M | 24.37 | |
| $109.97 | +1.94% | $52,541.14M | 27.05 | |
| $79.04 | +2.41% | $49,371.07M | 20.95 | |
| $45.91 | +2.55% | $47,390.78M | 16.15 | |
| $115.49 | +1.17% | $42,561.53M | 17.71 | |
| $114.63 | +3.74% | $37,352.07M | 20.63 |
An investment of $100 made 5 years ago in Fortis is now worth
$ 132.24
giving a profit of
$ 32.24 (32.24%)
Note: Past profits do not guarantee future returns.
